BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer
Adding a BRAF inhibitor and an EGFR antibody to first-line chemotherapy roughly doubled survival in BRAF V600E-mutated metastatic bowel cancer, one of the worst-prognosis subtypes.
Open-label phase 3 trial of patients with untreated BRAF V600E-mutated metastatic colorectal cancer randomised to encorafenib plus cetuximab plus mFOLFOX6, encorafenib plus cetuximab alone (arm later closed), or standard chemotherapy with or without bevacizumab. Primary endpoints were PFS and objective response rate.
The first report (Nature Medicine 2025) showed a response rate of about 61% vs 40%, supporting accelerated FDA approval in December 2024. The 2025 NEJM report showed median PFS 12.8 vs 7.1 months (HR 0.53) and median OS 30.3 vs 15.1 months (HR 0.49). It moved BRAF-targeted therapy from second line (BEACON) to first line and is the largest survival gain ever seen in this subgroup.
- Objective response about 61% vs 40% in the first analysis (Nature Medicine 2025), with longer duration of response.
- Median PFS 12.8 vs 7.1 months; HR 0.53.
- Median overall survival 30.3 vs 15.1 months; HR 0.49.
- Grade 3 or higher adverse events were more frequent with the triplet plus chemotherapy, driven by skin toxicity, gastrointestinal events and neutropenia.
- The chemotherapy-free encorafenib plus cetuximab arm was stopped early after emerging data from other studies.
Patients with newly diagnosed metastatic colorectal cancer whose tumour carries a BRAF V600E mutation, which is about 8-12% of cases, should now be offered encorafenib and cetuximab together with FOLFOX from the start rather than after chemotherapy fails; median survival has roughly doubled to about two and a half years. BRAF testing at diagnosis is therefore essential, alongside RAS and mismatch repair testing. The regimen is more toxic than chemotherapy alone.
- Open-label; some figures come from conference presentations and interim analyses, and long-term follow-up is short.
- Most patients had microsatellite-stable tumours; dMMR BRAF-mutated tumours should still receive immunotherapy first.
- Combination toxicity and cost are considerable; treatment requires three targeted or antibody agents plus chemotherapy.
- Resistance to BRAF/EGFR blockade remains universal; the trial does not address what follows.
Pages like this
not linked directly; found by shared links- TrialBREAKWATER
Shares Elena Élez, Josep Tabernero, Encorafenib, BRAF.
- Key paperKEYNOTE-177: pembrolizumab instead of chemotherapy as first treatment for mismatch-repair-deficient metastatic colorectal cancer
Shares Elena Élez, Tae Won Kim, Takayuki Yoshino, Lines of therapy.
- Key paperCodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer
Shares Tae Won Kim, Objective response rate (ORR), Monoclonal antibodies, Progression-free survival (PFS).
- Key paperKEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer
Shares Lines of therapy, Objective response rate (ORR), Overall survival (OS), Monoclonal antibodies.
- Key paperEV-302: enfortumab vedotin plus pembrolizumab replaces chemotherapy as first treatment for advanced bladder cancer
Shares Lines of therapy, Objective response rate (ORR), Pfizer (incl. Seagen), Too many combinations to test.
- Key paperCLEAR: lenvatinib plus pembrolizumab versus sunitinib as first treatment for advanced kidney cancer
Shares Lines of therapy, Objective response rate (ORR), Too many combinations to test, Overall survival (OS).
- Key paperCodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug
Shares Objective response rate (ORR), Accelerated approval, Overall survival (OS), Progression-free survival (PFS).
- IdeaProvisional prices for surrogate-endpoint approvals, reset when survival data arrive
Shares Accelerated approval, Overall survival (OS), Progression-free survival (PFS), Prices and value.